NeoGenomics Inc (NEO)

Debt-to-capital ratio

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Long-term debt	US$ in thousands	538,198	537,475	536,755	536,037	535,322	534,609	533,898	533,189	532,483	531,779	531,077	530,378	168,120	166,440	164,544	90,605	91,829	93,027	94,250	90,995
Total stockholders’ equity	US$ in thousands	941,537	947,428	956,192	974,462	998,023	1,012,990	1,043,520	1,075,000	1,108,280	1,137,240	1,148,360	843,714	694,294	666,363	654,229	505,043	507,408	497,007	489,734	323,848
Debt-to-capital ratio		0.36	0.36	0.36	0.35	0.35	0.35	0.34	0.33	0.32	0.32	0.32	0.39	0.19	0.20	0.20	0.15	0.15	0.16	0.16	0.22

December 31, 2023 calculation

Debt-to-capital ratio = Long-term debt ÷ (Long-term debt + Total stockholders’ equity)
= $538,198K ÷ ($538,198K + $941,537K)
= 0.36

The debt-to-capital ratio of Neogenomics Inc. has remained relatively stable in recent quarters, ranging between 0.33 and 0.36. This ratio measures the proportion of the company's capital that is financed by debt, with 0 representing no debt and 1 representing entirely debt-funded capital structure.

Neogenomics Inc. consistently maintains a conservative level of debt relative to its total capital, showing a prudent approach to managing its financial leverage. The stable trend in the debt-to-capital ratio indicates that the company has been able to maintain a healthy balance between debt and equity in its capital structure over the past few quarters.

Overall, a debt-to-capital ratio of around 0.35 suggests that Neogenomics Inc. relies moderately on debt financing as part of its overall capital structure, indicating a relatively low financial risk profile. It also indicates that the company has a good capacity to meet its debt obligations and suggests a stable long-term financial position.